Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023.
- Total revenue increased 8% annually to $1.60 billion in Q4, both on a reported basis and excluding the impact of foreign currency
- Women’s Health revenue increased 7% year-over-year, driven primarily by strong growth in Organon’s fertility products
- Biosimilar revenue jumped 49% from last year as reported, and 48% on an FX-adjusted basis in Q4
- Established Brands revenue rose 3%, despite the impacts of Volume-Based Procurement initiatives and a challenging operating environment in China
- Q4 net income more than doubled to $546 million or $2.13 per share in the three months ended December 2023
- On an adjusted basis, earnings moved up to $0.88 per share in Q4 from $0.81 per share last year
- At $449 million, fourth-quarter adjusted EBITDA was up 18% from the year-ago quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
HPE Earnings: Hewlett Packard Q2 profit drops but beats Street view
Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) on Thursday reported a year-over-year decline in earnings for the second quarter of 2024. Earnings, however, topped expectations. April-quarter profit, excluding
Broadcom (AVGO) preparing to report Q2 earnings. Here’s what to expect
Semiconductor firm Broadcom, Inc. (NASDAQ: AVGO) has been focused on its booming AI chip business lately, which is expected to account for about a fifth of the company’s revenue this
A few points of note from Dollar General’s (DG) Q1 2024 performance
Shares of Dollar General Corporation (NYSE: DG) fell over 1% on Tuesday. The stock has dropped 11% over the past three months. The discount store chain saw sales increase year-over-year in
